Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind active-controlled study of Pien Tze Huang as second-line treatment for unresectable primary liver cancer
CTR20213258Phase 2Active
- Sponsor
- Zhangzhou Pien Tze Huang Pharmaceutical
- Start
- Jan 2022
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of Pien Tze Huang in hepatocellular carcinoma (HCC), sponsored by Zhangzhou Pien Tze Huang Pharmaceutical. Started Jan 2022; status: active.
02
Drugs
Pien Tze Huang
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on CTR20213258.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20213258.